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Background: Identification and quantification of fibrillar amyloid in brain using positron emission tomography (PET)
imaging and Amyvid™ ([18 F] Amyvid, [18 F] florbetapir, 18 F-AV-45) was recently approved by the US Food and Drug
Administration as a clinical tool to estimate brain amyloid burden in patients being evaluated for cognitive
impairment or dementia. Imaging with [18 F] florbetapir offers in vivo confirmation of the presence of cerebral
amyloidosis and may increase the accuracy of the diagnosis and likely cause of cognitive impairment (CI) or
dementia. Most importantly, amyloid imaging may improve certainty of etiology in situations where the differential
diagnosis cannot be resolved on the basis of standard clinical and laboratory criteria.
Results: A consecutive case series of 30 patients (age 50-89; 16 M/14 F) were clinically evaluated at a cognitive
evaluation center of urban dementia center and referred for [18 F] florbetapir PET imaging as part of a
comprehensive dementia workup. Evaluation included neurological examination and neuropsychological
assessment by dementia experts. [18 F] florbetapir PET scans were read by trained nuclear medicine physicians
using the qualitative binary approach. Scans were rated as either positive or negative for the presence of
cerebral amyloidosis. In addition to a comprehensive dementia evaluation, post [18 F] florbetapir PET imaging
results caused diagnoses to be changed in 10 patients and clarified in 9 patients. Four patients presenting with
SCI were negative for amyloidosis. These results show that [18 F] florbetapir PET imaging added diagnostic
clarification and discrimination in over half of the patients evaluated.
Conclusions: Amyloid imaging provided novel and essential data that: (1) caused diagnosis to be revised;
and/or (2) prevented the initiation of incorrect or suboptimal treatment; and/or (3) avoided inappropriate
referral to an anti-amyloid clinical trial.
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Diagnosis and treatment of Alzheimer’s disease (AD) has
been hindered by the lack of affirmative, non-invasive
in vivo measures to identify the hallmark neuropathology
of the disease. To date, an accurate and definitive diagno-
sis of AD can only be determined at postmortem examin-
ation. The reliance on pathological reports places living
patients seeking accurate diagnosis, and ultimately appro-
priate treatment, at risk for misidentification of disease
due to overlap in clinical presentation, especially in early
stages of disease. Further, the absence of an affirmative
diagnostic test can lead to uncertainty and psychological
distress among patients and caregivers, due to equivocal
findings that are ultimately costly and frustrating. Binary
reading of retention of Amyvid™ (also known as [18 F] flor-
betapir; 18 F-AV-45; [18 F] Amyvid) has been approved re-
cently by the US Food and Drug Administration (FDA) as
a clinical tool for physicians to estimate cerebral fibrillar
amyloid burden in patients being evaluated for cognitive
impairment or dementia. Imaging with [18 F] florbetapir
could potentially: (1) increase confidence and accuracy of
the clinical diagnosis of AD; (2) rule out the presence of
amyloid thereby suggesting an alternative cause of CI; and
(3) clarify confusion due to the overlap between symptoms
of AD and those of other neurodegenerative diseases.
Many patients with AD go undiagnosed within primary
care settings [1]. Fewer than half of patients with dementia
have a documented diagnosis in their primary care medical
records, especially in milder or earlier stages of disease [2].
The use of biomarkers that identify amyloid pathology
could lead to more confident diagnosis and symptom man-
agement by primary care physicians as well as specialists.
We present here the impact of [18 F] florbetapir imaging
on clinical practice related to the diagnosis and treatment
of patients being evaluated for cognitive decline.
Research studies have shown that [18 F] florbetapir has
high affinity and specificity to fibrillar assemblies of the
amyloid-β peptide [3]. The ligand enters the brain quickly
once injected, demonstrates separation between individ-
uals with and without amyloid within 30 minutes, and
plateaus within 50 minutes [3]. A 10-minute scan at 50-
60 minutes post-injection is considered optimal. [18 F] flor-
betapir has a 110-minute half-life, allowing a substantial
time frame for delivery to imaging sites. The relatively
brief 10-minute scan time makes [18 F] florbetapir imaging
ideally suited in an older and potentially frail cohort.
The use of [18 F] florbetapir PET imaging has been vali-
dated against neuropathology in late stage disease to en-
sure that the imaging signal corresponds to the underlying
amyloid pathology [4,5]. In two recent prospective studies
evaluating whether [18 F] florbetapir PET imaging per-
formed during life is predictive of presence of cerebral
amyloidosis using immunohistochemistry and silver stain
at autopsy [4,6], visual binary reads (positive vs. negativefor amyloid) of the imaging and postmortem results for
the presence of amyloidosis were in agreement in 96% of
cases in a cohort of late stage dementia patients who died
within one year or less [4]. In a follow-up study in a larger
sample and in individuals who reached autopsy within
24 months of [18 F] florbetapir PET imaging, Clark et al.
[6], again using a binary visual read approach by trained
nuclear medicine physicians, replicated their initial find-
ings that sensitivity and specificity were 92% and 100%,
respectively, in a sub-sample who had autopsy within
24 months and were 96% and 100%, respectively in a sub-
sample who had autopsy within 12 months [6]. In addition
to validation of the binary visual read method (which is
now the standard approved for clinical use in the USA),
semi-quantitative analysis with [18 F] florbetapir PET im-
aging in six regions of interest was closely correlated with
postmortem amyloid burden in the patients who had aut-
opsy within 12 and 24 months (both p < 0.0001) [6].
However, recent evaluation of the clinicoradiological
correlation of amyloid imaging in early stage AD reveals
that as many as 30% of patients with clinically probable
AD referred for clinical trials have negative amyloid im-
aging despite the presence of both clinical symptoms
and radiological evidence of neurodegeneration by hip-
pocampal volumetry and PET imaging with [18 F] fluoro-
deoxyglucose [7]. This has led to the proposal that
neuroimaging criteria be employed for the designation
of some patients as having “amyloid-first” AD and others
as having “neurodegeneration-first”AD [7].
Mount Sinai Hospital was the first site in New York State
approved to conduct clinical [18 F] florbetapir PET imaging
by expert dementia clinicians and neuroimaging specialists.
Since FDA approval for clinical use in April 2012, we have
conducted [18 F] florbetapir imaging in 30 patients using a
binary read approach (positive or negative for brain amyl-
oid) by nuclear medicine physicians trained to interpret
[18 F] florbetapir PET scans. To our knowledge, this is the
first consecutive case series demonstrating the utility of
[18 F] florbetapir imaging in clinical practice in patients
seeking evaluation at a large, urban dementia center. Un-
like research studies designed either to determine validity
of the technology or conducted in highly selected cohorts
in which participants are rigidly screened to meet distinct
study inclusion criteria (i.e., AD or MCI or healthy, age-
matched controls) and exclude certain types of co-morbid
disorders [4,6-12], our clinical sample presented herein
are patients typically seen in our tertiary care clinical prac-
tice for dementia evaluation, and therefore the full range
of illnesses/co-morbidities and complex, atypical presenta-
tions seen in a typical aging cohort is represented.
Results and discussion
As part of the comprehensive dementia evaluation,
patients received the following diagnoses: probable AD
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n = 1), mild cognitive impairment (MCI), amnestic type
(n = 1), static memory impairment (n = 1), frontotemporal
lobar degeneration (FTLD), behavioral variant (n = 1),
FTLD, primary progressive aphasia type (n = 1), fronto-
temporal dementia, behavioral variant (n = 2), fronto-
temporal dementia, primary progressive aphasia (n = 1),
subjective cognitive impairment (SCI) (n = 4), MCI or
pseudodementia due to depression or Bipolar I disorder
(n = 2), cognitive impairment with history of substance
abuse (n = 1), vascular dementia (n = 1), delayed post-
traumatic cognitive impairment (n = 1), and Parkinson’s
disease with depression (n = 1). As seen in Additional
file 1: Table S1, amyloid imaging results caused diagno-
ses to be changed in 10 patients and clarified in 9 pa-
tients. All patients presenting with SCI were negative
for amyloidosis.
This is the first consecutive case series report demon-
strating the value of using [18 F] florbetapir PET imaging
for affirmative diagnostic confirmation and/or discrimin-
ation in a clinical sample of patients seen for evaluation
at an urban, dementia center. We have shown that [18 F]
florbetapir PET imaging added diagnostic clarification in
over half of the patients evaluated. In patients with AD
or MCI, amnestic type, [18 F] florbetapir imaging was
positive and consistent with clinical diagnosis, support-
ing the use of [18 F] florbetapir PET imaging for diagnos-
tic certainty. Indeed, the term “prodromal AD” has been
suggested to replace the older term MCI when evidence
for cerebral amyloidosis is present [13]. [18 F] florbetapir
imaging may also help clarify diagnosis in patients who
present with clinical and cognitive profiles indistinguish-
able from those with AD but yet, on amyloid imaging,
lack readily detectable amyloidosis.
In contrast, patients in whom the etiology was unclear
and who presented with Parkinson’s disease, frontotem-
poral dementia of the primary progressive aphasic or
behavioral variant types, post-traumatic cognitive impair-
ment (Mitsis et al., in preparation), depressive pseudode-
mentia and/or bipolar disorder I, and with SCI were
negative, indicating the value of [18 F] florbetapir PET im-
aging in a tertiary, urban clinical population that included
patients with varied histories, backgrounds and comorbid
illnesses.
Overall, our findings support the clinical utility of [18 F]
florbetapir PET imaging as an additional biomarker tool in
the evaluation of patients with ÇI due to a variety of
causes. Three unusual cases were encountered:
 Patient 1 had been given various diagnoses prior to
our evaluation (FTD vs. AD). FTD is a clinical
syndrome that may include primary progressive
aphasia (PPA) or behavioral variant (bv). AD
pathology in the right distribution can mimic PPAor FTD, bv. [18 F] florbetapir scan was positive, adding
diagnostic clarification. Our post-scan diagnosis was
clinical syndrome of FTD, behavioral variant due to
Alzheimer's pathology (Additional file 1: Table S1).
 Patient 20 had experienced one significant blow to
the occipital region during a sports-related activity
and had an otherwise negative scan. The [18 F] flor-
betapir scan was focally positive at the point of im-
pact (Mitsis et al., in preparation).
 Patient 16 had experienced multiple concussions.
Based upon this patient’s cognitive profile, three
experienced dementia clinicians (SG, MS, EMM)
supported the inclusion of AD. However, the [18 F]
florbetapir PET scan was negative for amyloid, thus
preventing a misdiagnosis and potential enrollment in
an inappropriate clinical trial of an experimental
amyloid-reducing agent (Mitsis et al, in preparation).
To provide guidance to dementia care practitioners, as
well as patients and caregivers, the Alzheimer’s Association
and the Society of Nuclear Medicine and Molecular Im-
aging convened the Amyloid Imaging Taskforce (AIT) to
develop criteria for appropriate use of brain amyloid im-
aging based upon consensus of expert opinion [11,14,15].
Given the dearth of information on the clinical use and
utility of amyloid PET imaging, the criteria offer definitions
of the types of patients and clinical circumstances in which
amyloid PET imaging can be used reliably as well as
circumstances under which the amyloid scans may be un-
reliable. According to the AIT, uncertainties due to the
complexities of patient history and the inconsistencies in
examination results could be clarified by the incorporation
of amyloid imaging into clinical decision making in order
to either clarify the choices amongst various entities in the
differential diagnosis and/or to simplify the complexities
associated with evaluation [15]. Of course, as with any type
of diagnosis, this also requires a careful history, examin-
ation, and all other tools necessary and available toward
patient care. The AIT warns that amyloid imaging is not
equivalent to clinical diagnosis of AD and should be used
only as an additional tool.
Amyloid imaging could be used to diagnose patients
who present with cognitive complaints, in whom many
clinicians reflexively (and nihilistically) assume that the
diagnosis is AD. A negative result on [18 F] florbetapir
PET imaging adds another level of current certainty to
diagnosis and offers reassurance to the patient and may
provoke a more aggressive pursuit of other, potentially re-
versible causes. In addition, amyloid imaging may serve as
a baseline, as positive amyloid scans may be observed in
asymptomatic people who may or may not progress to
AD. Amyloid deposition precedes cognitive symptoms in
familial AD [16] and is believed to do so in most typical
sporadic AD [12]. To this end, positive amyloid imaging
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larly in normal aging [19]. However, we currently lack the
evidence upon which we could reliably and accurately ad-
vise such a patient as to whether or not he or she is des-
tined to develop AD, and, if so, when symptoms would be
predicted to present themselves. Therefore, AIT advises
against amyloid scanning in asymptomatic subjects.
According to the recent United States FDA regula-
tory guidelines for [18 F] florbetapir imaging, a negative
scan is useful in excluding an AD diagnosis, while a
positive scan is not necessarily definitive. We would
agree but argue also that in clinical practice and par-
ticularly in the cohort of patients presented herein, a
full dementia diagnostic evaluation that considers a
variety of biomarkers could be substantially strength-
ened by the addition of [18 F] florbetapir imaging in
order to enhance diagnostic certainty and to guide
intervention and treatment planning. In some cases,
[18 F] florbetapir imaging clarified diagnosis in patients
presenting with a cognitive profile similar to AD yet
had a negative scan (Additional file 1: Table S1, patients
13, 16, 20, 26). In the absence of [18 F] florbetapir im-
aging data, these patients would have been referred to a
clinical trial with an anti-amyloid agent, which would
have been inappropriate both in terms of prospects of
clinical benefit and in terms of reliable evaluation of effi-
cacy of the drugs under evaluation. The recent recognition
that sometimes clinical symptoms and neurodegeneration
precede imaging evidence for cerebral amyloidosis under-
scores the importance of amyloid imaging in determining
entry into all trials of amyloid-reducing agents [7]. In
order to avoid the enrollment of subjects without
amyloidosis into trials of amyloid-reducing agents, the
Center for Medicare and Medicaid Services (CMS) has
agreed to cover one amyloid imaging scan per patient
as a part of the trial screening process (http://www.
cms.gov/medicare-coverage-database/details/nca-deci-
sion-memo.aspx?NCAId=265). In contrast, the value
of [18 F] florbetapir imaging in other circumstances has
been questioned by the CMS, prompting the recent de-
cision by CMS not to cover routine [18 F] florbetapir
imaging in Medicare patients (http://www.cms.gov/
medicare-coverage-database/details/nca-decisionmemo.
aspx?NCAId=265). The CMS ruling was based on the
fact that there is no disease-modifying drug available
for the treatment of AD, and that there is currently no
evidence that early diagnosis modifies the outcome.
Conclusions
Unlike research studies based in Alzheimer’s Disease Re-
search Centers and memory clinics that are enriched for
patients with likely or probable AD, our experience reflects
results from a clinical sample of patients who presented for
a comprehensive dementia evaluation at an urban medicalpractice and were referred for [18 F] florbetapir PET im-
aging for diagnostic identification. It has been our experi-
ence with these cases that [18 F] florbetapir PET imaging
added meaningful diagnostic clarification and certainty. For
some patients, that clarification led to a change in their
treatment protocol. In some instances, we were able to as-
sist amyloid-positive patients and their families in planning
for the future in terms of appropriate care and treatment,
as well as long-term personal decision making by the pa-
tients themselves. Finally, for individuals who were amyloid
positive, we were able to offer information to patients and
their families or caregivers regarding the opportunity to en-
roll in clinical trials of amyloid-reducing agents and other
therapeutic agents.
Methods
Patient demographics and evaluation
A consecutive case series of 30 patients (age 50-89; 16 M/
14 F) who were evaluated clinically and referred for [18 F]
florbetapir PET imaging for diagnostic confirmation and/
or clarification is presented. Patient education ranged be-
tween 12 and 20 years (high school graduate to advanced
degrees). Patients had a number of comorbid medical con-
ditions and were taking varied medications at the time of
[18 F] florbetapir PET imaging (Additional file 1: Table S1).
All patients underwent comprehensive history acquisition
and physical examination by a board-certified neurologist
or neuropsychiatrist (SG, MG, or AA). Clinical neuro-
psychological assessment by PhD level neuropsychologists
(HB, JM, JW, and MCS) was conducted on most patients;
n = 19). All practitioners were experts in the evaluation
and diagnosis of neurodegenerative disorders. Clinical
diagnoses were made prior to scanning based upon phys-
ician global clinical impression and neurocognitive met-
rics. One patient had lumbar puncture for extraction of
CSF for tau and Aβ42 biomarker analysis. Trained nuclear
medicine physicians (LK, JM), using the qualitative, binary
visual approach, rated the scans as positive or negative for
amyloid. Fifteen patients had had at least one brain MRI
within 6 months of the [18 F] florbetapir PET imaging (see
Additional file 1: Table S1).
[18 F] Florbetapir PET image acquisition
The camera used for [18 F] florbetapir PET/CT Brain Im-
aging was a GE Discovery STE 16-slice PET/CT Camera.
Patients were injected with 370 MBq (10 mCi) of [18 F]
florbetapir. Image acquisition began approximately 60 mi-
nutes post injection for all patients. Florbetapir was well
tolerated, and there were no adverse events. Images were
acquired in 3-D, for 10 minutes, using a one frame and
one bed position. Reconstruction was performed with a
120 × 120 matrix utilizing Iterative Reconstruction, with
35 Subsets and 2 Iterations. The Z-axis filter is standard,
and the post filter is a 2.57 mm FWHM (full width/half
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with 47 total slices.[18 F] Florbetapir PET image interpretation
We adhered to the practices in clinical nuclear medicine
of binary, visual reading of Amyvid scans and as outlined
by the FDA regarding [18 F] florbetapir PET imaging
(Amyvid®) for these clinical cases. This approach is con-
sistent with the recommendation put forth by both the
FDA and Avid Pharmaceuticals (Eli Lilly subsidiary;
makers of the ligand) for interpreting florbetapir scans in
clinical practice. In fact, to our knowledge it is the only
training method for reading of [18 F] florbetapir PET im-
aging (Amyvid®) scans offered by Avid Pharmaceuticals to
nuclear medicine physicians. As such, we sought to valid-
ate this approach in a typical, heterogeneous sample pre-
senting at our dementia center, as it will be the method
used in most clinical settings outside of research. The lim-
itations to using the visual read approach only is that the
findings are: 1) in the eye of the rater and 2) we run the
risk of not identifying regionally specific findings of amyl-
oid accumulation. It is important to note that our raters
were nuclear medicine physicians who underwent inten-
sive training in the visual read approach by the principals
at Avid Pharmaceuticals prior to reading the scans. In
addition, our raters began by using a consensus approach
for the first several patients (n < 5) and were in complete
agreement on all the initial cases. Because of the high level
of agreement between the two readers, the scan results for
the remaining patients are based upon the visual, binary
read of each reader independently.
Transaxial, coronal and sagittal images were examined.
Uptake in the cerebral cortex was compared to that in the
cerebellar and cerebral white matter tracts, both of which
normally have high non-specific uptake, while cerebral
gray matter normally has low uptake. A study was consid-
ered positive if uptake in the cerebral gray matter equaled
or exceeded the uptake in the white matter in at least two
major areas of the brain. A positive [18 F] florbetapir scan
indicates moderate to frequent fibrillar amyloid plaques. A
negative [18 F] florbetapir scan indicates sparse to no fibril-
lar amyloid plaques and was inconsistent with a diagnosis
of AD. A negative scan suggests that a patient’s cognitive
decline was not due to AD. Notable potential confounds
include: (1) the recent recognition of “neurodegeneration-
first” AD [7], the neuropathology of which remains to be
established; and (2) the unreliability of amyloid imaging
agents to recognize accumulation of oligomeric assemblies
of the amyloid-beta peptide [20].
Additional file
Additional file 1: Table S1. Patient demographics, scan outcomes.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EMM contributed to acquisition of data, drafted the manuscript and agrees
to be accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part of the work are appropriately
investigated and resolved. HB conducted neuropsychological evaluation of
patients and provided revisions to initial drafts of the manuscript. JM, MCS,
JW conducted neuropsychological evaluation of patients. LK and JM read
the results of each patient’s [18 F] florbetapir scan and provided feedback to
the manuscript. MG and AA provided patients for the series and feedback on
manuscript draft. MS participated in the case series design and provided
critical feedback to initial drafts. SG participated in the case series design and
coordination and provided critical feedback to initial and subsequent drafts.
All authors read and approved the final manuscript.
Acknowledgements
The Authors gratefully acknowledge Ash Rafique and Corey Fernandez for
technical and administrative support, respectively. SG thanks NIA, NINDS, the
Cure Alzheimer’s Fund, the Department of Veteran Affairs, the Gideon and
Sarah Gartner Foundation, and the Louis B. Mayer Foundation. Within the
past 5 years, SG has received grants from Baxter Pharmaceuticals,
Polyphenolics, Inc., and Amicus Pharmaceuticals. He has served as a member
of the Data and Safety Monitoring Board for the Pfizer-Janssen Alzheimer’s
Immunotherapy Alliance, as a member of the Scientific Advisory Board of
DiaGenic, and as a consultant to Amicus Pharmaceuticals and to Cerora, Inc.
This research was supported in part by the Icahn School of Medicine
Alzheimer’s Disease Research Center grant P50 AG05138.
Author details
1Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One
Gustave L. Levy Place, Box 1230, New York, NY 10029, USA. 2Department of
Neurology, New York, NY 10029, USA. 3Department of Nuclear Medicine,
New York, NY 10029, USA. 4Icahn School of Medicine at Mount Sinai,
Alzheimer’s Disease Research Center, One Gustave L. Levy Place, Box 1230,
New York, NY 10029, USA. 5James J. Peters Veterans Affairs Medical Center,
Bronx, NY 10468, USA.
Received: 31 December 2013 Accepted: 30 January 2014
Published: 3 February 2014
References
1. Solomon PR, Brush M, et al: Identifying dementia in the primary care
practice. Int Psychogeriatr 2000, 12(4):483–493.
2. Lopponen M, Raiha I, et al: Diagnosing cognitive impairment and
dementia in primary health care – a more active approach is needed.
Age Ageing 2003, 32(6):606–612.
3. Wong DF, Rosenberg PB, et al: In vivo imaging of amyloid deposition in
Alzheimer disease using the radioligand 18F-AV-45 (florbetapir
[corrected] F 18). J Nucl Med 2010, 51(6):913–920.
4. Clark CM, Schneider JA, et al: Use of florbetapir-PET for imaging
beta-amyloid pathology. JAMA 2011, 305(3):275–283.
5. Lister-James J, Pontecorvo MJ, et al: Florbetapir f-18: a histopathologically
validated Beta-amyloid positron emission tomography imaging agent.
Semin Nucl Med 2011, 41(4):300–304.
6. Clark CM, Pontecorvo MJ, et al: Cerebral PET with florbetapir compared
with neuropathology at autopsy for detection of neuritic amyloid-beta
plaques: a prospective cohort study. Lancet Neurol 2012, 11(8):669–678.
7. Jack CR Jr, Wiste HJ, et al: Amyloid-first and neurodegeneration-first
profiles characterize incident amyloid PET positivity. Neurology 2013,
81(20):1732–1740.
8. Doraiswamy PM, Sperling RA, et al: Amyloid-beta assessed by florbetapir F
18 PET and 18-month cognitive decline: a multicenter study.
Neurology 2012, 79(16):1636–1644.
9. Fleisher AS, Chen K, et al: Apolipoprotein E epsilon4 and age effects on
florbetapir positron emission tomography in healthy aging and
Alzheimer disease. Neurobiol of aging 2013, 34(1):1–12.
10. Fleisher AS, Chen K, et al: Using positron emission tomography and
florbetapir F18 to image cortical amyloid in patients with mild cognitive
Mitsis et al. Molecular Neurodegeneration 2014, 9:10 Page 6 of 6
http://www.molecularneurodegeneration.com/content/9/1/10impairment or dementia due to Alzheimer disease. Archives of Neurol
2011, 68(11):1404–1411.
11. Johnson KA, Minoshima S: Appropriate use criteria for amyloid PET:
a report of the amyloid imaging task force, the Society of Nuclear
Medicine and Molecular Imaging, and the Alzheimer's Association.
Alzheimers Dement 2013, 9(1):1–16.
12. Sperling RA, Johnson KA, et al: Amyloid deposition detected with
florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory
performance in clinically normal older individuals. Neurobiol Aging 2013,
34(3):822–831.
13. Albert MS, DeKosky ST, et al: The diagnosis of mild cognitive impairment
due to Alzheimer's disease: recommendations from the National
Institute on Aging-Alzheimer's Association workgroups on diagnostic
guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):270–279.
14. Johnson KA, Minoshima S, et al: Update on appropriate use criteria for
amyloid PET imaging: dementia experts, mild cognitive impairment, and
education. J Nucl Med 2013, 54(7):1011–1013.
15. Johnson KA, Sperling RA: Florbetapir (F18-AV-45) PET to assess amyloid
burden in Alzheimer's disease dementia, mild cognitive impairment, and
normal aging. Alzheimers Dement 2013, 9(5 Suppl):572–583.
16. Bateman RJ, Xiong C: Dominantly Inherited Alzheimer Network. Clinical
and biomarker changes in dominantly inherited Alzheimer's disease.
N Engl J Med 2012, 30(9):795–804. 367.
17. Mintun MA, Larossa GN, et al: [11C]PIB in a nondemented population:
potential antecedent marker of Alzheimer disease. Neurology 2006,
67(3):446–452.
18. Pike KE, Savage G, et al: Beta-amyloid imaging and memory in
non-demented individuals: evidence for preclinical Alzheimer's disease.
Brain 2007, 130(Pt 11):2837–2844.
19. Rosenberg PB, Wong DF, et al: Cognition and amyloid load in Alzheimer
disease imaged with florbetapir F 18(AV-45) positron emission
tomography. Am J Geriatr Psychiatry 2013, 21(3):272–278.
20. Scholl M, Wall A, et al: Low PiB PET retention in presence of pathologic
CSF biomarkers in Arctic APP mutation carriers. Neurology 2012,
79(3):229–236.
doi:10.1186/1750-1326-9-10
Cite this article as: Mitsis et al.: A consecutive case series experience
with [18 F] florbetapir PET imaging in an urban dementia center: impact
on quality of life, decision making, and disposition. Molecular
Neurodegeneration 2014 9:10.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
